A Single-center, Open-label Study to Investigate the Effect of a Single Oral Dose and Repeated Oral Doses of ID-082 on the Pharmacokinetics of Midazolam and Its Metabolite 1-hydroxymidazolam in Healthy Male Subjects.
Latest Information Update: 13 Feb 2020
At a glance
- Drugs ID-082 (Primary) ; Midazolam
- Indications Anxiety disorders
- Focus First in man; Pharmacodynamics
- Sponsors Idorsia Pharmaceuticals
- 08 Feb 2020 Results published in the Journal of Clinical Pharmacology
- 11 Jan 2018 Status changed from recruiting to completed.
- 12 Dec 2017 New trial record